#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Epilepsy with myoclonic-atonic seizures Hereditary angioedema with C1 esterase inhibitor deficiency Ornithine transcarbamoylase deficiency Glycogen storage disease type I Huntington's disease Juvenile idiopathic arthritis Penile squamous cell carcinoma Ocular lymphoma Ovarian cancer Neoplasm Thyroid cancer metastatic Prophylaxis against transplant rejection Congenital myopathy Primary adrenal insufficiency Hypoxic-ischaemic encephalopathy More trials…

    Learn about Rare Diseases

    Gaucher’s disease type I – Treatment Alagille syndrome – Trials in Disease Pemphigoid – Trials in Disease Hepatoblastoma – Treatment Waldenstrom’s macroglobulinaemia recurrent VEXAS syndrome – Diagnostics Systemic sclerosis pulmonary Mantle cell lymphoma – Basic Information Mucopolysaccharidosis III – Trials in Disease Angiosarcoma metastatic More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Colesevelam Birtamimab Corifollitropin Alfa Tacrolimus Monohydrate Spiramycin Depemokimab Contezolid Alirocumab Ecubectedin Ferric Carboxymaltose Basiliximab ARLOCABTAGENE AUTOLEUCEL SOFOSBUVIR ALLERGEN EXTRACTS Selinexor Setanaxib Verapamil Tisagenlecleucel Milvexian Streptococcus Agalactiae More therapies…

    Learn about Your Condition

    Vascular malformation Carotid artery stenosis Hypoxia Femoral neck fracture End stage renal disease Limb reduction defect Metastases to rectum Methylmalonic acidaemia Hypopituitarism Childhood asthma Hypophosphatasia Epileptic encephalopathy Univentricular heart Cortisol abnormal Vulval cancer recurrent More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Type 2 diabetes mellitus

  • Study of semaglutide effects on inflammation markers in patients with type 2 diabetes mellitus who have high cardiovascular risk

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Semaglutide
    Italy

  • Study on Switching from Dulaglutide to Tirzepatide for Adults with Type 2 Diabetes

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Bromocriptine
    • Canagliflozin
    • Colesevelam
    Belgium France Germany Romania

  • A Phase III Study of Elecoglipron Compared with Semaglutide for Adults with Type 2 Diabetes Mellitus

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Azd5004
    • Semaglutide
    Bulgaria Germany Hungary Italy Poland

  • A study testing ALN-4324 for safety and effectiveness in overweight to obese patients with type 2 diabetes

    Not recruiting

    2 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • ALN-4324
    Germany Poland

  • Study comparing cagrilintide and semaglutide versus tirzepatide in people with type 2 diabetes taking metformin or SGLT2 inhibitor

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Tirzepatide
    • Cagrilintide
    • Semaglutide
    Germany Greece Hungary Poland Romania Spain

  • A study testing cagrilintide and semaglutide combination for kidney damage in people with chronic kidney disease and type 2 diabetes who are overweight or obese

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    • Chronic kidney disease
    • Obesity
    Investigated Drugs:
    • Dapagliflozin Propanediol
    • Enalapril Maleate
    • Finerenone
    France Greece Hungary Poland Slovakia Spain
Previous Page
1 … 4 5 6 7 8 … 13
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!